Meningococcal group C disease in Greece during 1993-2006: The impact of an unofficial single-dose vaccination scheme adopted by most paediatricians

Clinical Microbiology and Infection

Volumn 13, Issue 5, 2007, Pages 550-552

  Kafetzis, D A ^a   Stamboulidis, K N ^a   Tzanakaki, G ^b   Kremastinou, J Kourea ^b   Skevaki, C L ^a   Konstantopoulos, A ^a   Tsolia, M ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NSPH   (Greece)

Author keywords

Conjugate vaccine; Epidemiology; Greece; Meningococcal C disease; Neisseria meningitidis; Vaccination strategy

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; GREECE; HUMAN; MENINGOCOCCOSIS; PEDIATRICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SINGLE DRUG DOSE; VACCINATION;

NEISSERIA MENINGITIDIS;

EID: 34147131383     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01704.x     Document Type: Article

References (10)

1. Kremastinou J, Tzanakaki G, Kansouzidou A et al. Recent emergence of serogroup C meningococcal disease in Greece. FEMS Immunol Med Microbiol 1999; 23: 49-55.
2. Tsolia M, Theodoridou M, Tzanakaki G et al. Invasive meningococcal disease in children in Greece: Comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis 2006; 25: 449-456.
3. Levy-Bruhl D, Perrocheau A, Taha M-K et al. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dome (France). Euro Surveill 2002; 5: 74-76.
4. Larrauri A, Cano R, Garcia M et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005; 32: 4097-4100.
5. De Wals P. Meningococcal C vaccines: The Canadian experience. Pediatr Infect Dis 2004; 23(suppl): S280-S284.
6. Ramsay M, Andrews N, Trotter C et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 2003; 326: 365-366.
7. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51: 717-722.
8. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005; 162: 89-100.
9. Trotter CL, Andrews NJ, Kaczmarski EB et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-367.
10. Snape DM, Kelly F, Green B et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis 2005; 24: 128-131.